Obatala Sciences, a New Orleans, LA-based biotechnology company, raised $3M in Series A funding.
The round was led by être Venture Capital and Ochsner Lafayette General Healthcare Innovation Fund II with participation from Benson Capital Partners, Elevate Capital Fund, and The Hackett-Robertson-Tobe Group.
The company intends to use the funds to further the commercialization of its research-enabling products and platform for drug discovery and development.
Led by CEO Trivia Frazier, Obatala Sciences enables diversity in clinical research and speeds up the development of therapies for diseases like obesity, diabetes, and cancer, and advance research in tissue engineering and regenerative medicine. The company has an established pipeline of human-derived hydrogels for growing cells in 3D, adult human stem cells from a biobank of diverse populations, media for growing and differentiating cells, and complete tissue chip kits, such as fat-on-a-chip systems, which are currently available, and pancreas-on-a-chip systems, which are under development.
FinSMEs
14/10/2022